Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study

Yu Zhang, Shuo Cao, Nan Niu, Huilian Shan, Jinqi Xue, Guanglei Chen, Yongqing Xu, Jianqiao Yin, Chao Liu, Lisha Sun, Xiaofan Jiang, Meiyue Tang, Qianshi Xu, Mingxuan Jia, Xu Zhang, Zhenyong Zhang, Qingfu Zhang, Jianfei Wang, Ailin Li, View ORCID ProfileYongliang Yang, View ORCID ProfileCaigang Liu
doi: https://doi.org/10.1101/2024.08.31.24312890
Yu Zhang
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
4Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuo Cao
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nan Niu
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huilian Shan
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinqi Xue
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guanglei Chen
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongqing Xu
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianqiao Yin
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chao Liu
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisha Sun
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaofan Jiang
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meiyue Tang
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qianshi Xu
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingxuan Jia
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xu Zhang
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhenyong Zhang
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qingfu Zhang
5Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianfei Wang
6Jiangsu Hengrui Pharmaceuticals, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ailin Li
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongliang Yang
7School of Bioengineering, Dalian University of Technology, Dalian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yongliang Yang
  • For correspondence: liucg{at}sj-hospital.org
Caigang Liu
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Caigang Liu
  • For correspondence: liucg{at}sj-hospital.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Article Information

doi 
https://doi.org/10.1101/2024.08.31.24312890
History 
  • February 7, 2025.

Article Versions

  • Version 1 (September 1, 2024 - 20:24).
  • You are viewing Version 2, the most recent version of this article.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Yu Zhang1,2,3,4,
  2. Shuo Cao1,
  3. Nan Niu1,2,3,
  4. Huilian Shan1,
  5. Jinqi Xue1,2,3,
  6. Guanglei Chen1,2,3,
  7. Yongqing Xu1,
  8. Jianqiao Yin1,
  9. Chao Liu1,2,3,
  10. Lisha Sun1,2,3,
  11. Xiaofan Jiang1,2,3,
  12. Meiyue Tang1,
  13. Qianshi Xu1,2,
  14. Mingxuan Jia1,
  15. Xu Zhang1,
  16. Zhenyong Zhang1,
  17. Qingfu Zhang5,
  18. Jianfei Wang6,
  19. Ailin Li1,
  20. Yongliang Yang7,* and
  21. Caigang Liu1,2,3,*
  1. 1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
  2. 2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
  3. 3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
  4. 4Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China
  5. 5Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, China
  6. 6Jiangsu Hengrui Pharmaceuticals, Shanghai, China
  7. 7School of Bioengineering, Dalian University of Technology, Dalian, China
  1. ↵*Corresponding author: Caigang Liu, MD, PhD, Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, China, Tel.: 86-18940254967, E-mail: liucg{at}sj-hospital.org
  1. Authors’ contributions: Y. Zhang, Data curation, formal analysis, methodology. S. Cao, Data curation, formal analysis, methodology, writing–original draft. N. Niu, Validation, data curation, formal analysis, methodology, writing–review and editing. H. Shan, Data curation, methodology. J. Xue, Data curation, methodology. G. Chen, Data curation, methodology. Y. Xu, Methodology. J. Yin, Methodology. C. Liu, Formal analysis, methodology. L. Sun, Methodology. X. Jiang, Writing-original draft. M. Tang, Data curation. Q. Xu, Formal analysis. M. Jia, Methodology. X. Zhang, Methodology. Z. Zhang, Methodology. Q. Zhang, Formal analysis. J. Wang, Methodology. A. Li, Conceptualization, methodology. Y. Yang, Methodology, writing–review and editing. Caigang Liu, Conceptualization, supervision, project administration, writing–review and editing. Yu Zhang, Shuo Cao, Nan Niu, Huilian Shan and Jinqi Xue contributed equally to this work.

Back to top
PreviousNext
Posted February 07, 2025.
Download PDF
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
Yu Zhang, Shuo Cao, Nan Niu, Huilian Shan, Jinqi Xue, Guanglei Chen, Yongqing Xu, Jianqiao Yin, Chao Liu, Lisha Sun, Xiaofan Jiang, Meiyue Tang, Qianshi Xu, Mingxuan Jia, Xu Zhang, Zhenyong Zhang, Qingfu Zhang, Jianfei Wang, Ailin Li, Yongliang Yang, Caigang Liu
medRxiv 2024.08.31.24312890; doi: https://doi.org/10.1101/2024.08.31.24312890
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
Yu Zhang, Shuo Cao, Nan Niu, Huilian Shan, Jinqi Xue, Guanglei Chen, Yongqing Xu, Jianqiao Yin, Chao Liu, Lisha Sun, Xiaofan Jiang, Meiyue Tang, Qianshi Xu, Mingxuan Jia, Xu Zhang, Zhenyong Zhang, Qingfu Zhang, Jianfei Wang, Ailin Li, Yongliang Yang, Caigang Liu
medRxiv 2024.08.31.24312890; doi: https://doi.org/10.1101/2024.08.31.24312890

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3292)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13374)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3268)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14627)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1705)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)